XETRA - Delayed Quote EUR

BioNTech SE (22UA.DE)

82.40

-1.20

(-1.44%)

As of 9:19:31 AM GMT+2. Market Open.

BioNTech SE (BNTX): Among the Best Growth Stocks to Buy and Hold for the Long Term

We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold for the Long Term. In this article, we are going to take a look at where BioNTech SE (NASDAQ:BNTX) stands against the other growth stocks. What’s the Bull Case for US Equities? The market closed last week mostly lower, however, the […]

Insider Monkey yesterday

BNTX
BioNTech (NasdaqGS:BNTX) Appoints New CFO As Q1 Sales Fall To €183 Million

BioNTech (NasdaqGS:BNTX) recently appointed Ramón Zapata-Gomez as its new CFO, a move reflecting the company's focus on realigning its financial strategy, particularly in oncology. Despite confirming its earnings guidance for 2025, the company's Q1 performance showed a continued net loss, highlighting financial challenges. Over the past month, the company's share price moved 15%, amidst a market environment where indices like the Dow Jones and Nasdaq showed mixed responses to broader economic...

Simply Wall St. 8 days ago

BNTX
Correction: European Equities Close Mixed in Monday Trading; Shell Mulls Acquiring BP

(Corrects to remove the reference to the FTSE 100 in the first and fourth paragraphs, which closed M

PREMIUM
MT Newswires 8 days ago

SAN

BNTX
BioNTech First Quarter 2025 Earnings: Beats Expectations

BioNTech ( NASDAQ:BNTX ) First Quarter 2025 Results Key Financial Results Revenue: €182.8m (down 2.6% from 1Q 2024...

Simply Wall St. 8 days ago

BNTX
BioNTech SE (BNTX) Q1 2025 Earnings Call Highlights: Navigating Challenges and Advancing ...

Despite a net loss, BioNTech SE (BNTX) remains focused on oncology advancements and maintains a strong financial position with significant cash reserves.

GuruFocus.com 9 days ago

BNTX
Q1 2025 Biontech SE Earnings Call

Q1 2025 Biontech SE Earnings Call

Thomson Reuters StreetEvents 9 days ago

BNTX
European Equities Close Mixed in Monday Trading; Shell Mulls Acquiring BP

The European stock markets closed mixed in Monday trading as The Stoxx Europe 600 was up 0.19%, Germ

PREMIUM
MT Newswires 9 days ago

SAN

BNTX

^FTSE
BioNTech Maintains Full-Year Revenue Outlook Despite Surprise Quarterly Sales Decline

BioNTech (BNTX) on Monday reiterated its full-year revenue outlook despite reporting an unexpected d

PREMIUM
MT Newswires 9 days ago

BNTX
BioNTech Announces First Quarter 2025 Financial Results and Corporate Update

Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA cancer immunotherapies Presented multiple clinical updates across oncology pipeline underlining BioNTech’s combination strategy in oncology with first data presented for the novel combination of BNT327 plus antibody-drug conjugates (“ADCs”) Development and commercial preparation for a 2025/2026 seaso

GlobeNewswire 9 days ago

BNTX
BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer

Mainz, Germany, May 5, 2025 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Ramón Zapata-Gomez to the Management Board as Chief Financial Officer (“CFO”) effective July 1, 2025. He will join BioNTech from Novartis AG’s global biomedical research organization where he has been serving as CFO since 2022. Ramón Zapata will succeed Jens Holstein, who, as previously planned and announced, will retire at the end of his

GlobeNewswire 9 days ago

BNTX
Stocks to watch this week: Palantir, TSMC, Novo Nordisk and JD Wetherspoon

Earnings preview of key companies reporting this week and what to look out for.

Yahoo Finance UK 10 days ago

ARM

NXGPF

NXGPY
Akeso survival data for ivonescimab misses expectations, STAT says

While Akeso (AKESF) and Summit Therapeutics’ (SMMT) ivonescimab, a rival to Merck’s (MRK) Keytruda, won approval in China this week, the data on patient survival did not meet analyst expectations, Jonathan Wosen of STAT reports. In its submission to regulators, Akeso included data on patient survival, disclosing that an interim analysis following 157 patient deaths found that participants on ivonescimab had a roughly 22% reduced risk of death, with a hazard ratio of 0.784, a company spokesperson

TipRanks 18 days ago

MRK

SMMT

BNTX
Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today

Both U.S.-based Summit Therapeutics (NASDAQ: SMMT) and BioNTech (NASDAQ: BNTX) were down significantly, plunging 36.1% and 15.4%, respectively, in Friday's trading. The severe moves were likely related to a Chinese rival in the PD-1/VEGF bispecific antibody area, Akeso (OTC: AKES.F), receiving FDA approval for a cancer drug that utilizes similar technology, as well as an additional approval in China. As a result, Akeso shares were up 11.7% on Friday.

Motley Fool 19 days ago

SMMT

BNTX

AKESF
BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025

MAINZ, Germany, April 24, 2025 -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will present data for selected assets from its diversified oncology pipeline, including mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies, at the American Association for Cancer Research (“AACR”) Annual Meeting held in Chicago, Illinois from April 25-30, 2025. The oral and poster presentations underline both the progress of BioNTech’s advanced priority oncology programs a

GlobeNewswire 20 days ago

BNTX
Novavax (NVAX) Surges 19.5%: Is This an Indication of Further Gains?

Novavax (NVAX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks 21 days ago

NVAX

BNTX
BioNTech Surges On Summit's Coattails. But Can They Take On Merck?

BioNTech stock rocketed Wednesday after rival Summit Therapeutics unveiled promising results for a novel approach to lung cancer treatment.

Investor's Business Daily 21 days ago

BNTX

MRK

SMMT
BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025

MAINZ, Germany, April 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the first quarter 2025 on Monday, May 5, 2025. Additionally, the Company will host a conference call and webcast that day at 8:00 a.m. EDT (2:00 p.m. CEST) for investors, financial analysts and the general public to discuss its financial results and provide a corporate update. To access the live conference call via telephone, please register via this

GlobeNewswire 22 days ago

BNTX
BioNTech SE (BNTX) Q4 2024 Earnings Call Highlights: Navigating Challenges and Advancing Innovations

BioNTech SE (BNTX) reports a net profit for Q4 2024 amidst a challenging year, with strategic advancements in oncology and infectious diseases.

GuruFocus.com 23 days ago

BNTX
Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?

BioNTech (BNTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks 29 days ago

BNTX
BioNTech (NasdaqGS:BNTX) Sees 11% Stock Increase Over Last Week

BioNTech (NasdaqGS:BNTX) saw its share price increase by 11%, coinciding with significant market activity and major index gains. While the company itself did not have any significant news or announcements within that week, the broader market trends, including technology stocks gaining momentum due to tariff exemptions, likely buoyed BioNTech amidst a sector-wide lift. The broader positive market sentiment, demonstrated by a 5.8% rise, provided a favorable backdrop for the company's stock...

Simply Wall St. 30 days ago

BNTX

Performance Overview

Return	22UA.DE	MSCI WORLD (^990100-USD-STRD)
YTD	-25.09%	+3.17%
1-Year	-3.74%	+10.17%
3-Year	-43.35%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

BioNTech SE (22UA.DE)

BioNTech SE (BNTX): Among the Best Growth Stocks to Buy and Hold for the Long Term

BioNTech (NasdaqGS:BNTX) Appoints New CFO As Q1 Sales Fall To €183 Million

Correction: European Equities Close Mixed in Monday Trading; Shell Mulls Acquiring BP

BioNTech First Quarter 2025 Earnings: Beats Expectations

BioNTech SE (BNTX) Q1 2025 Earnings Call Highlights: Navigating Challenges and Advancing ...

Q1 2025 Biontech SE Earnings Call

European Equities Close Mixed in Monday Trading; Shell Mulls Acquiring BP

BioNTech Maintains Full-Year Revenue Outlook Despite Surprise Quarterly Sales Decline

BioNTech Announces First Quarter 2025 Financial Results and Corporate Update

BioNTech Announces Appointment of Ramón Zapata to Management Board as Chief Financial Officer

Stocks to watch this week: Palantir, TSMC, Novo Nordisk and JD Wetherspoon

Akeso survival data for ivonescimab misses expectations, STAT says

Why Biotech Stars Summit Therapeutics and BioNTech Plunged, Even as This Chinese Rival Surged Today

BioNTech to Present Clinical and Preclinical Data Across mRNA and Next-Generation Immuno-Oncology Priority Programs at AACR 2025

Novavax (NVAX) Surges 19.5%: Is This an Indication of Further Gains?

BioNTech Surges On Summit's Coattails. But Can They Take On Merck?

BioNTech to Report First Quarter 2025 Financial Results and Corporate Update on May 5, 2025

BioNTech SE (BNTX) Q4 2024 Earnings Call Highlights: Navigating Challenges and Advancing Innovations

Strength Seen in BioNTech (BNTX): Can Its 6.0% Jump Turn into More Strength?

BioNTech (NasdaqGS:BNTX) Sees 11% Stock Increase Over Last Week

Performance Overview